TOP > 外国特許検索 > PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE

PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE

外国特許コード F150008420
掲載日 2015年10月9日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP051202
国際公開番号 WO 2014119438
国際出願日 平成26年1月22日(2014.1.22)
国際公開日 平成26年8月7日(2014.8.7)
優先権データ
  • 特願2013-014263 (2013.1.29) JP
発明の名称 (英語) PROPHYLACTIC OR THERAPEUTIC DRUG FOR INFARCTION DISEASE
発明の概要(英語) Provided is a therapeutic drug for an infarction disease, in particular, a drug that is capable of exhibiting a therapeutic effect on the infarction disease even in the case where said drug is administered 3 hours or longer after the onset of regional ischemia. A prophylactic or therapeutic drug for an infarction disease, said drug containing an RANKL protein.
従来技術、競合技術の概要(英語) BACKGROUND ART
The disease is cerebral infarction such as myocardial infarction or infarcted, ischemic vascular occlusion or the like due to the occurrence of the site. Typically, ischemia having a portion in such a way that a portion of the perimeter and thus can encourage the oxygen and nutrient, further at the same time or in accordance with this inflammatory response occurs by free radical production, increased with necrosis site a short period of time. Therefore, for the treatment of diseases is infarct, ischemia after the occurrence of the site, administering a therapeutic effective at a relatively early stage is extremely important.
As such therapeutic agents, internationally recognized effectiveness include, for example thrombolytic drugs (tissue plasminogen activator) has been known. However, the thrombolytic agent is, after the occurrence of the ischemic site within 3 since the time required to be administered, the time of occurrence of ischemic site which has already been completely unknown patient 3 time passes after the occurrence of the ischemic site and cannot be used by the patient. Therefore, after the occurrence of the ischemic site after time passes 3 administered infarcted disease development of therapeutics to exert effects is demanded.
RANKL(Receptor Activator of NF κB Ligand) activating osteoclasts promote bone resorption by well known as a factor. In part, in order to inhibit the inflammatory cytokine RANKL is reported (non-patent document 1) but, in the first place RANKL is, as its name indicates NFκB (inflammatory cytokine IL-6 and having a function of promoting the expression of TNF α) was discovered as a factor for activating since, and inhibit inflammatory responses actually RANKL infarction diseases whether or not the therapeutic effect is unknown. In addition, inhibit inflammatory responses to steroid therapy is effective against diseases not infarcted in view of these circumstances, it is possible to suppress the inflammatory response simply infarct effective for the treatment of diseases is unknown whether any of the said.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA UNIVERSITY
  • 発明者(英語)
  • SHIMAMURA, Munehisa
  • NAKAGAMI, Hironori
  • OSAKO, Mariana Kiomy
  • MORISHITA, Ryuichi
  • KURINAMI, Hitomi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close